FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149990240> ?p ?o ?g. }

• W3149990240 endingPage "2154" @default.
• W3149990240 startingPage "2143" @default.
• W3149990240 abstract "Accelerated endothelial healing after targeted antiproliferative drug delivery may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel Supreme DES is designed to synchronize early drug delivery within 4 to 6 weeks of implantation, leaving behind a prohealing permanent base layer. Whether the Supreme DES is safe and effective in the short term and can improve long-term clinical outcomes is not known.In an international, 2:1 randomized, single-blind trial, we compared treatment with Supreme DES to durable polymer everolimus-eluting stents (DP-EES) in patients with acute and chronic coronary syndromes. The primary end point was target lesion failure-a composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. The trial was designed to demonstrate noninferiority (margin of 3.58%) of the Supreme DES at 12 months compared with DP-EES (URL: https://www.clinicaltrials.gov; Unique identifier: NCT03168776).From October 2017 to July 2019, a total of 1629 patients were randomly assigned (2:1) to the Supreme DES (N=1086) or DP-EES (N=543). At 12 months, target lesion failure occurred in 57 of 1057 patients (5.4%) in the Supreme DES group and in 27 of 532 patients (5.1%) in the DP-EES group (absolute risk difference, 0.32% [95% CI, -1.87 to 2.5]; Pnoninferiority=0.002]. There were no significant differences in rates of device success, clinically driven target lesion revascularization, or stent thrombosis at 12 months, and the safety composite of cardiovascular death and target vessel myocardial infarction was 3.5% versus 4.6% (hazard ratio, 0.76 [95% CI, 0.46-1.25]) with Supreme DES compared with DP-EES, although rates of combined clinically and non-clinically driven target lesion revascularization at 12 months were higher with Supreme DES.Among patients with acute and chronic coronary syndromes undergoing percutaneous coronary intervention, the Supreme DES proved to be noninferior to the standard DP-EES. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03168776." @default.
• W3149990240 created "2021-04-13" @default.
• W3149990240 creator A5011133072 @default.
• W3149990240 creator A5011403969 @default.
• W3149990240 creator A5012791093 @default.
• W3149990240 creator A5013515607 @default.
• W3149990240 creator A5013586115 @default.
• W3149990240 creator A5014857861 @default.
• W3149990240 creator A5021162166 @default.
• W3149990240 creator A5039632207 @default.
• W3149990240 creator A5039638882 @default.
• W3149990240 creator A5041084808 @default.
• W3149990240 creator A5041859498 @default.
• W3149990240 creator A5043877348 @default.
• W3149990240 creator A5048066946 @default.
• W3149990240 creator A5048845661 @default.
• W3149990240 creator A5051494975 @default.
• W3149990240 creator A5052462864 @default.
• W3149990240 creator A5053194091 @default.
• W3149990240 creator A5055357489 @default.
• W3149990240 creator A5063210480 @default.
• W3149990240 creator A5065394674 @default.
• W3149990240 creator A5068388388 @default.
• W3149990240 creator A5070039427 @default.
• W3149990240 creator A5074461963 @default.
• W3149990240 creator A5079151837 @default.
• W3149990240 creator A5082003758 @default.
• W3149990240 creator A5091436608 @default.
• W3149990240 date "2021-06-01" @default.
• W3149990240 modified "2023-10-17" @default.
• W3149990240 title "Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial" @default.
• W3149990240 cites W1432324221 @default.
• W3149990240 cites W146325010 @default.
• W3149990240 cites W1482348910 @default.
• W3149990240 cites W1849785625 @default.
• W3149990240 cites W1997760014 @default.
• W3149990240 cites W2031572147 @default.
• W3149990240 cites W2080770108 @default.
• W3149990240 cites W2087150869 @default.
• W3149990240 cites W2092998815 @default.
• W3149990240 cites W2096321722 @default.
• W3149990240 cites W2101986337 @default.
• W3149990240 cites W2118462279 @default.
• W3149990240 cites W2119470649 @default.
• W3149990240 cites W2122779695 @default.
• W3149990240 cites W2135807965 @default.
• W3149990240 cites W2331820709 @default.
• W3149990240 cites W2333500897 @default.
• W3149990240 cites W2615022822 @default.
• W3149990240 cites W2620950555 @default.
• W3149990240 cites W2747702104 @default.
• W3149990240 cites W2752033985 @default.
• W3149990240 cites W2759236937 @default.
• W3149990240 cites W2768525260 @default.
• W3149990240 cites W2772242654 @default.
• W3149990240 cites W2777748294 @default.
• W3149990240 cites W2887297392 @default.
• W3149990240 cites W2888902549 @default.
• W3149990240 cites W2889254142 @default.
• W3149990240 cites W2904005713 @default.
• W3149990240 cites W2905547914 @default.
• W3149990240 cites W2915744897 @default.
• W3149990240 cites W2970313195 @default.
• W3149990240 cites W3018450694 @default.
• W3149990240 cites W3048551738 @default.
• W3149990240 cites W3081167346 @default.
• W3149990240 cites W3184177771 @default.
• W3149990240 cites W4205653014 @default.
• W3149990240 cites W4236531408 @default.
• W3149990240 cites W51319040 @default.
• W3149990240 cites W584804003 @default.
• W3149990240 cites W6602297 @default.
• W3149990240 doi "https://doi.org/10.1161/circulationaha.120.052482" @default.
• W3149990240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33820424" @default.
• W3149990240 hasPublicationYear "2021" @default.
• W3149990240 type Work @default.
• W3149990240 sameAs 3149990240 @default.
• W3149990240 citedByCount "15" @default.
• W3149990240 countsByYear W31499902402021 @default.
• W3149990240 countsByYear W31499902402022 @default.
• W3149990240 countsByYear W31499902402023 @default.
• W3149990240 crossrefType "journal-article" @default.
• W3149990240 hasAuthorship W3149990240A5011133072 @default.
• W3149990240 hasAuthorship W3149990240A5011403969 @default.
• W3149990240 hasAuthorship W3149990240A5012791093 @default.
• W3149990240 hasAuthorship W3149990240A5013515607 @default.
• W3149990240 hasAuthorship W3149990240A5013586115 @default.
• W3149990240 hasAuthorship W3149990240A5014857861 @default.
• W3149990240 hasAuthorship W3149990240A5021162166 @default.
• W3149990240 hasAuthorship W3149990240A5039632207 @default.
• W3149990240 hasAuthorship W3149990240A5039638882 @default.
• W3149990240 hasAuthorship W3149990240A5041084808 @default.
• W3149990240 hasAuthorship W3149990240A5041859498 @default.
• W3149990240 hasAuthorship W3149990240A5043877348 @default.
• W3149990240 hasAuthorship W3149990240A5048066946 @default.
• W3149990240 hasAuthorship W3149990240A5048845661 @default.
• W3149990240 hasAuthorship W3149990240A5051494975 @default.
• W3149990240 hasAuthorship W3149990240A5052462864 @default.

• next